cccdna

ccc_R08 is an orally available HBV cccDNA inhibitor that reduces extracellular levels of HBV DNA, HBsAg, and HBeAg in a dose-dependent manner. ccc_R08 is investigational for use in the treatment of HBV infections. ccc_R08 has been shown to be effective in the treatment of hepatitis C virus (HCV).

RO8191 (CDM-3008) (CDM-3008) is an agonist of interferon (IFN) receptor.

GLP-26 disrupts the encapsidation of pre-genomic RNA, causes nucleocapsid disassembly and reduces cccDNA pools. GLP-26 is a HBV capsid assembly modulators (CAM), inhibits HBV DNA replication in Hep AD38 system (IC50=3 nM), and reduces cccDNA by >90% at 1

Bentysrepinine, a novel anti-HBV agent, inhibits DNA-HBV and cccDNA activities for the treatment of hepatitis B virus (HBV)-infected hepatitis.

HBV-IN-25 is a novel chemical compound that acts as a potent HBV cccDNA reducer when administered orally. It exhibits significant anti-HBeAg potency and anti-HBV activity, with IC50 values of 0.58 μM and 1.15 μM, respectively. Moreover, HBV-IN-25 demonstrates favorable aqueous solubility (LYSA＞452 μg mL) and no cellular toxicity, making it a promising candidate for further investigation and development [1].

HBV-IN-16 is a quinoline derivative, which has an effective inhibitory effect on covalent closed circular DNA (cccDNA). CccDNA is the template for viral RNA transcription and subsequent viral DNA generation. HBV-IN-16 has potential in the research of HBV infection.

HBV-IN-14 is a pyridinopyrimidinone compound and a potent covalent closed-loop DNA (cccDNA) inhibitor. HBV-IN-14 has potential for the study of HBV infection.

Clevudine (Levovir) is a synthetic pyrimidine analogue with activity against hepatitis B virus (HBV). Intracellularly, clevudine is phosphorylated to its active metabolites, clevudine monophosphate and triphosphate. The triphosphate metabolite competes with thymidine for incorporation into viral DNA, thereby causing DNA chain termination and inhibiting the function of HBV DNA polymerase (reverse transcriptase). Clevudine has a long half-life and shows significant reduction of covalently closed circular DNA (cccDNA), therefore the patient is less likely to have a relapse after treatment is discontinued.

Junceellolide C, a potent anti-HBV agent, acts as a transcription inhibitor of cccDNA, effectively inhibiting HBV DNA replication and significantly reducing supernatant HBV RNA levels in HepAD38 cells, with EC50 values of 5.19 and 3.52 μM, respectively.

Trans-ccc_R08 is a potent inhibitor of cccDNA (covalently closed circular DNA), displaying significant activity in decreasing HBeAg levels with an IC50 value of 0.08 µM. This compound shows promise for research into the treatment of Hepatitis B Virus (HBV) infection.

cis-ccc_R08 infection . cis-ccc_R08 is a cccDNA (covalently closed circular DNA) inhibitor .

HBV-IN-15, a flavone derivative, acts as a potent inhibitor of covalently closed circular DNA (cccDNA), which is crucial for viral RNA transcription and subsequent viral DNA production. This compound shows promise for research in Hepatitis B Virus (HBV) infection.

HBV-IN-29 (ex8), a flavone derivative, acts as a potent inhibitor of covalently closed circular DNA (cccDNA), crucial for viral RNA transcription and subsequent viral DNA replication, showing promise in HBV infection studies.

HBV-IN-30 (ex44), a flavone derivative, is a potent inhibitor of covalently closed circular DNA (cccDNA), which is crucial for viral RNA transcription and subsequent viral DNA production, showing promise for hepatitis B virus (HBV) infection research.

HBV-IN-31, a potent inhibitor of covalently closed circular DNA (cccDNA), demonstrates significant anti-HBV activity by inhibiting cell growth and exhibiting an IC50 value of 0.13 µM for HBsAg.

HBV-IN-32, a potent inhibitor of covalently closed circular DNA (cccDNA), exhibits significant anti-Hepatitis B Virus (HBV) activity by achieving an IC50 of 0.14 µM against HBsAg. Additionally, it impedes cell growth.